Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat 5-day nirmatrelvir/ritonavir for COVID-19 rebound
2022-002827-36Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Nirmatrelvir/ritonavir with Placebo/ritonavir (2 arms). Primary endpoint: Change in SARS-CoV-2 RNA level from baseline to Day 5. Started Oct 2022; status: completed.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-002827-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002827-36.